1 / 19

Amsterdam Life Sciences Café

Amsterdam Life Sciences Café. Jeroen Maas Amsterdam Economic Board. Marc ter Haar EY. W hat are we working on. 1) Infrastructure : - (Hardware) - Collaboration - Governance - FAIR data. 2) LSH Ecosystem - Capabilities - Players - Integration. 3) Data Analytics & Services

trombly
Download Presentation

Amsterdam Life Sciences Café

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Amsterdam Life Sciences Café

  2. Jeroen MaasAmsterdam Economic Board Marc ter HaarEY

  3. What are we working on 1) Infrastructure: - (Hardware) - Collaboration - Governance - FAIR data 2) LSH Ecosystem - Capabilities - Players - Integration 3) Data Analytics & Services - Connected value chain - Across health continuum - Across disciplines and sectors

  4. Board members Chair Femke Halsema Burgermeester van Amsterdam en voorzitter van de Amsterdam Economic Board en Amsterdam Network Council Governments Knowledge institutions Companies Barbara Baarsma Directievoorzitter Rabobank Amsterdam Jacqueline Cramer RegisseurCirculaire Economie Jaap Bond Gedeputeerde Provincie Noord Holland Hans Bakker Voorzitter VNO-NCW Metropoolregio Amsterdam Jeroen Tas Chief Innovation & Strategy Officer Philips Marcel van Loo Managing Partner EMEIA Financial Services EY Netherlands Wimar Jaeger Wethouder Gemeente Hilversum Geert ten Dam Voorzitter College van Bestuur Universiteit van Amsterdam André van den Berg Chief Commercial Officer Schiphol Group Ingrid Thijssen CEO Alliander Syro Ronda Senior Business Analyst Siemens Young on Board Udo Kock Wethouder Gemeente Amsterdam Huib de Jong Voorzitter College van Bestuur Hogeschool van Amsterdam Hans Fischer CEO Tata Steel Europe Henk Markerink CEO Amsterdam ArenA Roulerend lid Young on Board Franc Weerwind Burgemeester Gemeente Almere Chris Heutink Lid Raad van Bestuur Randstad Groep Nederland Joris Schoonis AVP Marketing Cloud Europe & Israel Salesforce Mirjam van Praag Voorzitter College van Bestuur Vrije Universiteit Erik Henstra Managing Director LeasePlan NL Yuri Sebregts Vice President Innovation and R&D and CTO Shell Hans Snijders Voorzitter College van Bestuur Nova College

  5. The European Biotechnology Start-up Landscape Rogier Rooswinkel

  6. Overview Forbion. 70 investments in EU and US 9 product launches Millions of people benefit from improvements made 12 years history of success Over €1B under management in 4 Investment Funds 3 Co-Investment-Funds 3 Seed funds (BGV) Based in the Netherlands and Germany • Fully life science focused • Team with complementing background: PhD’s, MD’s and investment bankers • Staying close to science and bioentrepreneurs

  7. Forbion “bioentrepreneur” business research publication series in Nature Biotechnology

  8. Emergingbiomedical companies drive drug development andinnovation • Emerging companies now control 72% of 2,853 late-stage drugs • Big Pharma’s share of the late-stage pipeline has plunged 20% IQVIA Pipeline Intelligence April 2018, IQVIA Institute May 2019

  9. So, what about the NL Biotech landscape?

  10. Period 2013-2017 (5 years) • Analysis restricted to countries with more than 1 million inhabitants and at least two start-ups within the study period • Considered Science, Patenting, VC presence and proxies to human capital Bonnie van Wilgenburg, Kim van Wilgenburg, Kathryn Paisner, Sander van Deventer and Rogier Rooswinkel. Nature Biotechnology April 2019

  11. The European Biotechnology Start-up Landscape Start-up defined as first time a company raises seed- or start-up capital (source: GlobalData Pharmaceutical database)

  12. European Biomedical Scientific Output As a proxy for research productivity, we used the total number of citable and non-citable documents published in the field of medicine in 2013–2017 obtained from Scimago

  13. European Biomedical Patenting Counted biotechnology patents filed per country/capita with Nat Biotech Patent lawyer

  14. European Life Science VC’s Selected VC firms that had done at least 5 new investments over the last 5 yrs (investments coming from Biocenturydb)

  15. Life Science Human Capital We mapped nations on the basis of the 2017 Global Entrepreneurship Index, GGDI Number of Principal investigators that started at least one clinical trial per year in the past 5 years (globaldata) “KOL’s ”

  16. What drives Biotech Start-up initiation in Europe? All factors combinedexplain 83% of the startup variation

  17. What can we do/should we not do in the Netherlands? • Invest in Science and education • Protect and respect intellectual property; professionalize tech transfer offices • Recognize the importance of Key Opinion Leaders/principle investigators (“large pharma prostitutes”) • Recognize the dramatic improvements in therapeutic efficacy and pay for innovative drugs • Facilitate, rather than block, innovative clinical development

  18. Contact us & stay in touch Central e-mail address for team LSH Amsterdam: lsh@amsterdam.nl Join other Amsterdam health innovators on our Linkedin group Amsterdam Health Ideas, suggestions & info:j.maas@amecboard.com

More Related